Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Scientific Enters Bridge Credit Agreement for up to €9.25 Billion

NEW YORK – Thermo Fisher Scientific said on Thursday that on April 17, it entered into a bridge credit agreement with JPMorgan Chase and Morgan Stanley Senior Funding for up to €9.25 billion ($9.96 billion).

The company had announced on March 3 that the lenders had committed to the debt financing in connection with its proposed acquisition of Qiagen.

Under the terms of the agreement, Thermo Fisher is obtaining a 364-day senior unsecured bridge loan facility in the principal amount of up to €9.25 billion. Loans under the agreement will be available to fund the purchase of equity securities of Qiagen and to pay all or a portion of the cost incurred in connection with this.

Thermo Fisher can draw on the funds on the closing date of the acquisition and again within 120 days after the closing date.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.